Clinical experience with erlotinib in non-small-cell lung cancer

Drugs of Today

Volumn 42, Issue 3, 2006, Pages 147-156

  Felip, Enriqueta ^a   Rosell, Rafael ^b,c  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c Medical Oncology Service   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BARBITURIC ACID DERIVATIVE; BEVACIZUMAB; CARBAMAZEPINE; CARBOPLATIN; CISPLATIN; CLARITHROMYCIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ERYTHROMYCIN; GEFITINIB; GEMCITABINE; ITRACONAZOLE; KETOCONAZOLE; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PEMETREXED; PERTUZUMAB; PHENYTOIN; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RIFAMPICIN;

BLOOD TOXICITY; CANADA; CANCER CELL; CANCER CELL CULTURE; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIVITY; EXON; EYE DISEASE; GENE DELETION; HUMAN; IN VITRO STUDY; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; POINT MUTATION; PROTEIN PHOSPHORYLATION; PROTEINURIA; RASH; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY; UNIVARIATE ANALYSIS;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33646242760     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2006.42.3.957358     Document Type: Review

References (49)

1. Non-small-Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995, 311: 899-909.
2. Rapp, E., Pater, J.L., Wilan, A. et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer - Report of a Canadian multicenter randomized trial. J Clin Oncol 1998, 6: 633-41.
3. Cardenal, F., López-Cabrerizo, M.P., Antón, A. et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 1999, 17: 12-8.
4. Le Chevalier, T., Brisgand, D., Douillard, J.I. et al. Randomized study of vinorelbine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 1994, 12: 360-7.
5. Rosell, R., Gatzemeier, U., Betticher, D. et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: A cooperative multinational trial. Ann Oncol 2002, 13: 1539-49.
6. Kelly, K., Crowley, J., Bunn, P.A. et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncoloy Group trial. J Clin Oncol 2001, 19: 3210-8.
7. Schiller, J.H., Harrington, D., Belani, C.H. et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346: 92-8.
8. Pfister, D.G., Johnson, D.H., Azzoli, C.G. et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 2004, 22: 330-53.
9. Alberola, V., Camps, C., Provencio, M. et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: A Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 2003, 21: 3207-13.
10. Shepherd, F.A., Dancey, J., Ramlau, R. et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18: 2095-103.
11. Hanna, N., Shepherd, F.A., Fossella, F.V. et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22: 1589-97.
12. Olayioye, M.A., Neve, R.M., Lane, H.A., Hynes, N.E. The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J 2000, 19:3159-67.
13. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103: 211-25.
14. Vivanco, I., Sawyers, C.L. The phosphatidylinositol 3-Kinase-Akt pathway in human cancer. Nat Rev Cancer 2002, 2: 489-501.
15. Rranklin, W.A., Veve, R., Hirsch, F.R. et al. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 2002, 29 (1 Suppl. 4): 3-14.
16. Meert, A.P., Martin, B., Delmotte, P. et al. The role of EGF-R expression on patient survival in lung cancer: A systematic review with meta-analysis. Eur Respir J 2002, 20: 975-81.
17. Hirsch, F.R., Varella-Garcia, M., Bunn, P.A. Jr. et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003, 21: 3798-807.
18. Blackhall, F.H., Rehman, S., Thatcher, N. Erlotinib in non-small cell lung cancer: A review. Expert Opin Pharmacother 2005, 6: 995-1002.
19. Johnson, J.R., Cohen, M., Sridhara, R. et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 2005, 11: 6414-21.
20. Cohen, M.H., Johnson, J.R., Chen, Y.F. et al. FDA drug approval summary: Erlotinib (Tarceva) tablets. The Oncologist 2005, 10: 461-6.
21. Karp, D.D., Silberman, S.L., Csudae, R. et al. Phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor OSI-774 in patients with advanced solid tumors. Proc Am Soc Clin Oncol 1999, 18: 388, Abst. 686.
22. Hidalgo, M., Siu, L.L., Neumunaitis, J. et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001, 19: 3267-79.
23. Pérez-Soler, R., Chachoua, A., Hammond, L.A. et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004, 22: 3238-47.
24. Amador, M.L., Oppenheimer, D., Perea, S. et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 2004, 64: 9139-43.
25. Pérez-Soler, R., Delord, J.P., Halpern, A. et al. HER1/EGFR inhibitor-associated rash: Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005, 10: 345-56.
26. Felip, E., Rojo, F., Heller, A. et al. Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy: Preliminary results. Proc Am Soc Clin Oncol 2005, 23: 645, Abst. 7100.
27. Miller, V.A., Hirsch, F.R., Johnson, D.H. Systemic therapy of advanced bronchioloalveolar cell carcinoma: Challenges and opportunities. J Clin Oncol 2005, 23: 3288-93.
28. Giaccone, G., Le Chevalier, T., Thatcher, N. et al. A phase II study of erlotinib as first-line in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2005, 23: 638, Abst. 7073.
29. Jackman, D., Lucca, J., Fidias, P. et al. Phase II study of the EGFR tyrosine kinase in patients ≥70 years of age with previously untreated advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2005, 23: 657, Abst. 7148.
30. Shepherd, F.A., Rodrigues Pereira, J., Ciuleanu, T. et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005, 353: 123-32.
31. Tsao, M.S., Sakurada, A., Cutz, J.C. et al. Erlotinib in lung cancer: Molecular and clinical predictors of outcome. N Engl J Med 2005, 353: 133-44.
32. Gatzemeier, U., Pluzanska, A., Szczesna, A. et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (CG) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004, 22: 617, Abstr. 7010.
33. Herbst, R.S., Prager, D., Hermann, R. et al. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23: 5892-99.
34. Lynch, T.J., Bell, D.W., Sordella, R. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004, 350: 2129-39.
35. Paez, J.G., Janne, P.A., Lee, J.C. et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004, 304: 1458-61.
36. Pao, W., Miller, V., Zakowski, M. et al. EGF receptor mutations are common in lung cancer from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004, 101: 13306-11.
37. Jänne, P.A., Engelman, J.A., Johnson, B.E. Epidermal growth factor receptor mutation in non-small-cell lung cancer: Implications for treatment and tumor biology. J Clin Oncol 2005, 23: 3227-34.
38. Johnson, B.E., Jänne, P.A. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res 2005, 65: 7525-9.
39. Taron, M., Ichinose, Y., Rosell, R. et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 2005, 11: 5878-85.
40. Cappuzzo, F., Hirsch, F.R., Rossi, E. et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005, 97: 643-55.
41. Shigematsu, H., Lin, L., Takahashi, T. et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005, 97: 339-46.
42. Pao, W., Wang, T.Y., Riely, G.J. et al. KRAS mutations and primary resistance of lung adenocarcinoma to gefitinib or elotinib. PLoS Med 2005, 2: e17.
43. Eberhard, D.A., Johnson, B.E., Amler, L.C. et al. Mutations in the epidermal growth factor receptor and KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005, 23: 5900-9.
44. Kobayashi, S., Boggon, T.J., Dayaram, T. et al. EGFR mutation and resistance of non-small cell lung cancer to gefitinib. N Engl J Med 2005, 325: 786-92.
45. Pao, W., Miller, V.A., Politi, K.A. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2: e73.
46. Kwak, E.L., Sordella, R., Bell, D.W. et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005, 102: 7665-70.
47. Kobayashi, S., Ji, H., Yuza, Y. et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res 2005, 65: 7096-101.
48. Herbst, R.S., Johnson, D.H., Mininberg, E. et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005, 23: 2544-55.
49. Friess, T., Scheuer, W., Hasmann, M. Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy. Clin Cancer Res 2005, 14: 5300-9.